# Roche

全球最大生物技术公司——单抗先驱，拥有赫赛汀/利妥昔单抗；完全整合的生物制造，涵盖分子诊断、生物分析和临床开发；SIX: ROG。

Source: https://cn.bioecon.ru/companies/roche/
Updated: 2026-06-19

- 国家: Switzerland
- 营收: CHF 58.7B
- 员工: ~100,000 emp

## 可核验事实

| 事实 | 数值 | 来源 |
| --- | --- | --- |
| 营收 | 瑞士法郎625.98亿 (2025-12-31) | https://www.contractpharma.com/top-company-profile/roche/ |
| 融资 | 五年内向美国制药与诊断领域投资$500亿 (2025-04-22) | https://assets.roche.com/f/308312/x/bdb6cdb7d2/ar25e.pdf, https://www.contractpharma.com/top-company-profile/roche/ |
| 生产基地 | 美国13个生产基地 (2025-04-22) | https://assets.roche.com/f/176343/b7b5afd2b3/01-22042025_mr_roche-us-investment_en.pdf, https://www.roche.com/media/releases/med-cor-2025-04-22 |
| 生产基地 | 北卡罗来纳州Holly Springs的65,000平方米生产设施 (2025-08-25) | https://www.contractpharma.com/top-company-profile/roche/, https://www.roche.com/media/releases/med-cor-2025-10-23 |
| 认证 | 通过EU-GMP、美国FDA、英国MHRA及日本PMDA认证的生产基地 (2026-06-01) | https://chemxpert.com/company-group-details?param2=manufacturing_locations-group&param3=eu--gmp-certified-site&value=Roche+Group, https://chemxpert.com/download-summary-company?value=Roche+International+Ltd, https://chemxpert.com/download-summary-company?value=Roche+Pharma+Ag+Switzerland |
| 监管批准 | Gazyva/Gazyvaro、Ocrevus Zunovo及Tecentriq Hybreza等多款生物制品获FDA与欧盟批准 (2025-12-31) | https://assets.roche.com/f/176343/x/ca13f631d1/29012026_mr_fy_roche2025_english.pdf, https://pharmadossier.com/blog/roche-genentech-portfolio-dossier-subcutaneous-biologics-access, https://www.roche.com/media/releases/med-cor-2025-10-23 |

独立来源: chemxpert.com, contractpharma.com, pharmadossier.com

## 技术

- [双特异性与多特异性抗体](https://cn.bioecon.ru/technology/bispecific-antibodies/)
- [生物药 (Biologics)](https://cn.bioecon.ru/technology/biologics/)
- [自动化核酸提取](https://cn.bioecon.ru/technology/automated-nucleic-acid-extraction/)
- [诊断与生物传感器](https://cn.bioecon.ru/technology/diagnostics-biosensors/)